Voclosporin

A potentially promising therapeutic agent for noninfectious uveitis

Yasir Jamal Sepah, Elizabeth Michelle, Brandon Metcalf, Afsheen Khwaja, Roomasa Channa, Mohamed Ibrahim, Elham Hatef, Jangwon Heo, Jeong Lee Hee, Zubir Samsuddin Rentiya, Diana V. Do, Quan Dong Nguyen

Research output: Contribution to journalArticle

Abstract

Voclosporin is a novel calcineurin inhibitor that functions by binding cyclophilin, consequently inhibiting calcineurin activity and preventing the transcription of many genes involved in lymphocyte proliferation and cytokine release. Voclosporin has been shown to be effective in a variety of autoimmune diseases, such as rheumatoid arthritis, psoriasis and renal transplant rejection. Noninfectious uveitis is also an immune-mediated disease which, if left untreated, can cause severe loss of vision. Presently, corticosteroids are the mainstay of therapy in noninfectious uveitis. However, there are several metabolic and ophthalmic adverse effects associated with the long-term use of corticosteroids. Voclosporin has recently been shown in the LX-211 Uveitis Multicenter Investigation of a New Approach to Treatment (LUMINATE) clinical trial program to be effective in the treatment of noninfectious uveitis. With an acceptable side-effects profile, voclosporin is an exciting addition to the therapeutic options available in the management of noninfectious uveitis.

Original languageEnglish (US)
Pages (from-to)281-286
Number of pages6
JournalExpert Review of Ophthalmology
Volume6
Issue number3
DOIs
StatePublished - Jun 2011

Fingerprint

Uveitis
Transplants
Lymphocytes
Transcription
Genes
Adrenal Cortex Hormones
Cyclophilins
Therapeutics
Calcineurin
Immune System Diseases
Graft Rejection
Psoriasis
Autoimmune Diseases
Rheumatoid Arthritis
voclosporin
Clinical Trials
Cytokines
Kidney

Keywords

  • autoimmune
  • calcineurin inhibitor
  • LUMINATE
  • uveitis
  • voclosporin

ASJC Scopus subject areas

  • Ophthalmology
  • Biomedical Engineering
  • Optometry

Cite this

Sepah, Y. J., Michelle, E., Metcalf, B., Khwaja, A., Channa, R., Ibrahim, M., ... Nguyen, Q. D. (2011). Voclosporin: A potentially promising therapeutic agent for noninfectious uveitis. Expert Review of Ophthalmology, 6(3), 281-286. https://doi.org/10.1586/eop.11.19

Voclosporin : A potentially promising therapeutic agent for noninfectious uveitis. / Sepah, Yasir Jamal; Michelle, Elizabeth; Metcalf, Brandon; Khwaja, Afsheen; Channa, Roomasa; Ibrahim, Mohamed; Hatef, Elham; Heo, Jangwon; Hee, Jeong Lee; Rentiya, Zubir Samsuddin; Do, Diana V.; Nguyen, Quan Dong.

In: Expert Review of Ophthalmology, Vol. 6, No. 3, 06.2011, p. 281-286.

Research output: Contribution to journalArticle

Sepah, YJ, Michelle, E, Metcalf, B, Khwaja, A, Channa, R, Ibrahim, M, Hatef, E, Heo, J, Hee, JL, Rentiya, ZS, Do, DV & Nguyen, QD 2011, 'Voclosporin: A potentially promising therapeutic agent for noninfectious uveitis', Expert Review of Ophthalmology, vol. 6, no. 3, pp. 281-286. https://doi.org/10.1586/eop.11.19
Sepah, Yasir Jamal ; Michelle, Elizabeth ; Metcalf, Brandon ; Khwaja, Afsheen ; Channa, Roomasa ; Ibrahim, Mohamed ; Hatef, Elham ; Heo, Jangwon ; Hee, Jeong Lee ; Rentiya, Zubir Samsuddin ; Do, Diana V. ; Nguyen, Quan Dong. / Voclosporin : A potentially promising therapeutic agent for noninfectious uveitis. In: Expert Review of Ophthalmology. 2011 ; Vol. 6, No. 3. pp. 281-286.
@article{4033052f384c44379234cd72332d9ab5,
title = "Voclosporin: A potentially promising therapeutic agent for noninfectious uveitis",
abstract = "Voclosporin is a novel calcineurin inhibitor that functions by binding cyclophilin, consequently inhibiting calcineurin activity and preventing the transcription of many genes involved in lymphocyte proliferation and cytokine release. Voclosporin has been shown to be effective in a variety of autoimmune diseases, such as rheumatoid arthritis, psoriasis and renal transplant rejection. Noninfectious uveitis is also an immune-mediated disease which, if left untreated, can cause severe loss of vision. Presently, corticosteroids are the mainstay of therapy in noninfectious uveitis. However, there are several metabolic and ophthalmic adverse effects associated with the long-term use of corticosteroids. Voclosporin has recently been shown in the LX-211 Uveitis Multicenter Investigation of a New Approach to Treatment (LUMINATE) clinical trial program to be effective in the treatment of noninfectious uveitis. With an acceptable side-effects profile, voclosporin is an exciting addition to the therapeutic options available in the management of noninfectious uveitis.",
keywords = "autoimmune, calcineurin inhibitor, LUMINATE, uveitis, voclosporin",
author = "Sepah, {Yasir Jamal} and Elizabeth Michelle and Brandon Metcalf and Afsheen Khwaja and Roomasa Channa and Mohamed Ibrahim and Elham Hatef and Jangwon Heo and Hee, {Jeong Lee} and Rentiya, {Zubir Samsuddin} and Do, {Diana V.} and Nguyen, {Quan Dong}",
year = "2011",
month = "6",
doi = "10.1586/eop.11.19",
language = "English (US)",
volume = "6",
pages = "281--286",
journal = "Expert Review of Respiratory Medicine",
issn = "1747-6348",
publisher = "Expert Reviews Ltd.",
number = "3",

}

TY - JOUR

T1 - Voclosporin

T2 - A potentially promising therapeutic agent for noninfectious uveitis

AU - Sepah, Yasir Jamal

AU - Michelle, Elizabeth

AU - Metcalf, Brandon

AU - Khwaja, Afsheen

AU - Channa, Roomasa

AU - Ibrahim, Mohamed

AU - Hatef, Elham

AU - Heo, Jangwon

AU - Hee, Jeong Lee

AU - Rentiya, Zubir Samsuddin

AU - Do, Diana V.

AU - Nguyen, Quan Dong

PY - 2011/6

Y1 - 2011/6

N2 - Voclosporin is a novel calcineurin inhibitor that functions by binding cyclophilin, consequently inhibiting calcineurin activity and preventing the transcription of many genes involved in lymphocyte proliferation and cytokine release. Voclosporin has been shown to be effective in a variety of autoimmune diseases, such as rheumatoid arthritis, psoriasis and renal transplant rejection. Noninfectious uveitis is also an immune-mediated disease which, if left untreated, can cause severe loss of vision. Presently, corticosteroids are the mainstay of therapy in noninfectious uveitis. However, there are several metabolic and ophthalmic adverse effects associated with the long-term use of corticosteroids. Voclosporin has recently been shown in the LX-211 Uveitis Multicenter Investigation of a New Approach to Treatment (LUMINATE) clinical trial program to be effective in the treatment of noninfectious uveitis. With an acceptable side-effects profile, voclosporin is an exciting addition to the therapeutic options available in the management of noninfectious uveitis.

AB - Voclosporin is a novel calcineurin inhibitor that functions by binding cyclophilin, consequently inhibiting calcineurin activity and preventing the transcription of many genes involved in lymphocyte proliferation and cytokine release. Voclosporin has been shown to be effective in a variety of autoimmune diseases, such as rheumatoid arthritis, psoriasis and renal transplant rejection. Noninfectious uveitis is also an immune-mediated disease which, if left untreated, can cause severe loss of vision. Presently, corticosteroids are the mainstay of therapy in noninfectious uveitis. However, there are several metabolic and ophthalmic adverse effects associated with the long-term use of corticosteroids. Voclosporin has recently been shown in the LX-211 Uveitis Multicenter Investigation of a New Approach to Treatment (LUMINATE) clinical trial program to be effective in the treatment of noninfectious uveitis. With an acceptable side-effects profile, voclosporin is an exciting addition to the therapeutic options available in the management of noninfectious uveitis.

KW - autoimmune

KW - calcineurin inhibitor

KW - LUMINATE

KW - uveitis

KW - voclosporin

UR - http://www.scopus.com/inward/record.url?scp=79959785460&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959785460&partnerID=8YFLogxK

U2 - 10.1586/eop.11.19

DO - 10.1586/eop.11.19

M3 - Article

VL - 6

SP - 281

EP - 286

JO - Expert Review of Respiratory Medicine

JF - Expert Review of Respiratory Medicine

SN - 1747-6348

IS - 3

ER -